Login / Signup

Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.

Luca QuartuccioArianna SonagliaDavide PecoriMaddalena PeghinMartina FabrisCarlo TasciniSalvatore De Vita
Published in: Journal of medical virology (2020)
Repeated measurement of the serum level of IL-6 early after tocilizumab may distinguish nonsurvivors from survivors and support the choice of deeper targeting IL-6 in COVID-19 pneumonia.
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • cancer therapy
  • rheumatoid arthritis patients
  • drug delivery
  • respiratory failure
  • disease activity